ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Purchased by Victory Capital Management Inc.

Victory Capital Management Inc. lifted its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 6.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 13,777 shares of the specialty pharmaceutical company’s stock after purchasing an additional 858 shares during the quarter. Victory Capital Management Inc. owned approximately 0.07% of ANI Pharmaceuticals worth $762,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in ANIP. Natixis Advisors LLC lifted its holdings in shares of ANI Pharmaceuticals by 56.2% in the 3rd quarter. Natixis Advisors LLC now owns 18,184 shares of the specialty pharmaceutical company’s stock valued at $1,085,000 after buying an additional 6,545 shares during the period. Thrivent Financial for Lutherans lifted its holdings in shares of ANI Pharmaceuticals by 2.3% in the 3rd quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock valued at $777,000 after buying an additional 299 shares during the period. Quest Partners LLC lifted its holdings in shares of ANI Pharmaceuticals by 141.1% in the 3rd quarter. Quest Partners LLC now owns 9,893 shares of the specialty pharmaceutical company’s stock valued at $590,000 after buying an additional 5,789 shares during the period. Segall Bryant & Hamill LLC lifted its holdings in shares of ANI Pharmaceuticals by 1.7% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 44,872 shares of the specialty pharmaceutical company’s stock valued at $2,677,000 after buying an additional 740 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of ANI Pharmaceuticals by 99.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 13,470 shares of the specialty pharmaceutical company’s stock valued at $804,000 after buying an additional 6,728 shares during the period. 76.05% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other ANI Pharmaceuticals news, VP Meredith Cook sold 400 shares of the firm’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $63.33, for a total transaction of $25,332.00. Following the transaction, the vice president now directly owns 80,545 shares in the company, valued at $5,100,914.85. This trade represents a 0.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Krista Davis sold 1,000 shares of the firm’s stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $60.86, for a total value of $60,860.00. Following the transaction, the senior vice president now owns 66,525 shares in the company, valued at approximately $4,048,711.50. This trade represents a 1.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 3,200 shares of company stock worth $191,776 over the last quarter. Corporate insiders own 12.70% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on ANIP shares. StockNews.com raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, March 14th. HC Wainwright reaffirmed a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, March 17th. Leerink Partners started coverage on ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price objective for the company. Guggenheim raised their price objective on ANI Pharmaceuticals from $84.00 to $86.00 and gave the company a “buy” rating in a research note on Wednesday, March 5th. Finally, JPMorgan Chase & Co. started coverage on ANI Pharmaceuticals in a research note on Wednesday, March 12th. They issued an “overweight” rating and a $85.00 price objective for the company. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $79.75.

ANI Pharmaceuticals Stock Performance

ANIP opened at $64.26 on Friday. The firm has a market cap of $1.40 billion, a PE ratio of -116.84 and a beta of 0.63. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The business has a fifty day simple moving average of $59.39 and a 200-day simple moving average of $58.17. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.50 and a fifty-two week high of $70.81.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.